Damae Medical, a Paris, France-based medtech company, closed a €2m funding.
Backers included Kurma Partners, Idinvest Partners, News Invest, Paris-Saclay Seed Fund co-managed by Partech Ventures, and private investors.
The company intends to use the funds to finance the development and CE marking of OCTAV®, which is scheduled for mid-2018.
Founded in September 2014 by Anaïs Barut, CEO, Damae Medical aims to provide dermatologists with a novel, in vivo imaging technology for a deep look into the skin. This technology enables cellular-resolution imaging of the skin similar to histology, without the need for tissue excision and processing. The company’s lead product, OCTAV®, aimed at the instant, non-invasive diagnosis of skin cancers, is currently tested at the CHU of Saint Etienne.
Patented in 2013, the innovative approach was invented by Pr. Arnaud Dubois from the Charles Fabry Laboratory, a joint research laboratory established by Institut d’Optique Graduate School and the CNRS (French National Research Agency), with the Université Paris-Sud as a cooperating institution.
Applications for this tool are the diagnosis, therapy, and followup care for a broad spectrum of skin conditions and pathologies.